175 related articles for article (PubMed ID: 26395315)
1. Cholesterol is a significant risk factor for non-alcoholic steatohepatitis.
Walenbergh SM; Shiri-Sverdlov R
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1343-6. PubMed ID: 26395315
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
Ding Y; Sun X; Chen Y; Deng Y; Qian K
Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
[TBL] [Abstract][Full Text] [Related]
3. Trypanosoma cruzi infection is a potent risk factor for non-alcoholic steatohepatitis enhancing local and systemic inflammation associated with strong oxidative stress and metabolic disorders.
Onofrio LI; Arocena AR; Paroli AF; Cabalén ME; Andrada MC; Cano RC; Gea S
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003464. PubMed ID: 25668433
[TBL] [Abstract][Full Text] [Related]
4. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
5. Naringenin reduces cholesterol-induced hepatic inflammation in rats by modulating matrix metalloproteinases-2, 9 via inhibition of nuclear factor κB pathway.
Chtourou Y; Fetoui H; Jemai R; Ben Slima A; Makni M; Gdoura R
Eur J Pharmacol; 2015 Jan; 746():96-105. PubMed ID: 25446569
[TBL] [Abstract][Full Text] [Related]
6. Effects of dietary fatty acids and cholesterol excess on liver injury: A lipidomic approach.
Serviddio G; Bellanti F; Villani R; Tamborra R; Zerbinati C; Blonda M; Ciacciarelli M; Poli G; Vendemiale G; Iuliano L
Redox Biol; 2016 Oct; 9():296-305. PubMed ID: 27639112
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
8. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
Sutti S; Bruzzì S; Albano E
Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
[TBL] [Abstract][Full Text] [Related]
9. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis.
Spahis S; Delvin E; Borys JM; Levy E
Antioxid Redox Signal; 2017 Apr; 26(10):519-541. PubMed ID: 27452109
[TBL] [Abstract][Full Text] [Related]
10. A concise review of non-alcoholic fatty liver disease.
Than NN; Newsome PN
Atherosclerosis; 2015 Mar; 239(1):192-202. PubMed ID: 25617860
[TBL] [Abstract][Full Text] [Related]
11. Platelet-activating factor modulates fat storage in the liver induced by a high-refined carbohydrate-containing diet.
de Oliveira MC; Menezes-Garcia Z; Arifa RD; de Paula TP; Andrade JM; Santos SH; de Menezes GB; de Souza Dda G; Teixeira MM; Ferreira AV
J Nutr Biochem; 2015 Sep; 26(9):978-85. PubMed ID: 26013469
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
Ibrahim SH; Hirsova P; Gores GJ
Gut; 2018 May; 67(5):963-972. PubMed ID: 29367207
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins.
Walenbergh SM; Koek GH; Bieghs V; Shiri-Sverdlov R
J Hepatol; 2013 Apr; 58(4):801-10. PubMed ID: 23183522
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.
Marra F; Gastaldelli A; Svegliati Baroni G; Tell G; Tiribelli C
Trends Mol Med; 2008 Feb; 14(2):72-81. PubMed ID: 18218340
[TBL] [Abstract][Full Text] [Related]
18. Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease.
Ercin CN; Dogru T; Genc H; Celebi G; Aslan F; Gurel H; Kara M; Sertoglu E; Tapan S; Bagci S; Rizzo M; Sonmez A
Metab Syndr Relat Disord; 2015 Sep; 13(7):319-25. PubMed ID: 26011302
[TBL] [Abstract][Full Text] [Related]
19. [NASH -- nonalcoholic steatohepatitis].
Blechacz B; Stremmel W
Z Gastroenterol; 2003 Jan; 41(1):77-90. PubMed ID: 12541180
[TBL] [Abstract][Full Text] [Related]
20. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans.
Männistö VT; Simonen M; Hyysalo J; Soininen P; Kangas AJ; Kaminska D; Matte AK; Venesmaa S; Käkelä P; Kärjä V; Arola J; Gylling H; Cederberg H; Kuusisto J; Laakso M; Yki-Järvinen H; Ala-Korpela M; Pihlajamäki J
Liver Int; 2015 Jul; 35(7):1853-61. PubMed ID: 25533197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
